Keywords: Bristol-Myrers Squibb, AstraZeneca, Dapagliflozin, Briinta, USA, FDA, Diabetes, Blood thinner
US FDA warns of bladder and breast cancer risk for Bristol-Myers/AstraZeneca diabetes drug dapagliflozin ahead of advisory
Article | 18 July 2011
Ahead of an advisory panel meeting scheduled for tomorrow (July 19) to discuss US drug major Bristol-Myers Squibb (NYSE; BMY) and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
